Biotech News

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

Aptevo Therapeutics (APVO)Aptevo Therapeutics2026-06-25 13:46 ESTPartnership

50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May 27, 2026 / Aptevo Therapeutics Inc.

Open original release

Related news

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

APVOAptevo Therapeutics2026-06-25 13:46 EST

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo to Participate in March 2026 Conferences

View all latest news

Aptevo Therapeutics

Aptevo Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

APVOAptevo Therapeutics2026-06-26 06:19 EST

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

APVOAptevo Therapeutics2026-06-26 06:19 EST

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

APVOAptevo Therapeutics2026-06-26 06:19 EST

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

APVOAptevo Therapeutics2026-06-26 06:19 EST

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

APVOAptevo Therapeutics2026-06-26 06:19 EST

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States